Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (1333)	10/26/1998 2:50:00 PM
From: ACC	Read Replies (1) \| Respond to of 2135

well, can't confirm that folkman and o'reilly had indeed posted on yahoo, but they did present earlier today "Antiangiogenic therapy of orthotopic human prostate cancer in mice guided by prostate-specific antigen (PSA)" A nice abstract that confirmed their previously published reports. Nothing ground-breaking. They used a model in which human prostate cancer was injected into mice prostate (as opposed to under the skin), and followed tumor growth by measuring PSA. They showed that tumor growth correlates with PSA levels, a nice means of following tumor recurrence if such a marker is available as it is in prostate ca. When the tumors were left alone, they grew to rather large sizes (25% body weight) before sacrificing the mice. When treated with mouse angiostatin, the tumors regressed, as determined by PSA levels of 0. After withdrawing therapy tumors did not recur. If they stopped the angiostatin early, and let the tumors recur, retreatment resulted in tumor regression. Again, nothing new. Also, hormone-resistant tumors were responsive to angiostatin (encouraging news, since anti-hormonal therapy is a mainstay of late prostate ca, with limited survival) The problem remains the same - production. Again, the authors commented that when AS/ES is produced in E. coli, immunoprecipitation is a problem. They did not comment any further on the success of other production vectors (baculvirus, etc). Finally, note that mouse AS/ES works better in mice than human AS/ES - again shouldn't be a surprise - it makes sense that the host protein would work better than a foreign protein, since the target is actually the host endothelial cell. No comments about when human trials were anticipated... FWIW, ACC